Traveling with Tresiba (Insulin Degludec): What Every Woman Needs to Know

Why Tresiba Is Particularly Travel-Friendly (and What Still Requires Planning)

Tresiba stands out among basal insulins because its duration of action exceeds 42 hours and its action profile is nearly flat, meaning there is no pronounced peak that forces rigid timing. A 2015 pharmacokinetic study in Diabetes Care confirmed that the half-life of insulin degludec is approximately 25 hours, about twice that of insulin glargine U-100. That long half-life is why the FDA-approved prescribing information allows dosing at any time of day, as long as you maintain at least 8 hours between injections.

That pharmacology is genuinely useful when you are boarding a red-eye to Tokyo or spending a week in a mountain time zone three hours behind your home city. The buffer built into the molecule absorbs modest schedule shifts without the glycemic wobble you might see with a shorter-acting basal insulin.

Travel still demands a plan, though. Altitude, unfamiliar food, stress hormones, heat on the tarmac, and disrupted sleep all affect insulin sensitivity independently of the drug itself.

The ±8-Hour Flexibility Rule Explained

The Tresiba FDA prescribing information states that if you miss your usual injection time, you may give it as soon as you remember, provided there is at least 8 hours until the next scheduled dose. In practice, endocrinologists apply that same 8-hour buffer to time-zone transitions: you can delay or advance your injection by up to 8 hours on the travel day without requiring a supplemental correction dose in most cases.

For larger time-zone jumps, a common approach is to split the adjustment over two days rather than trying to shift the full difference at once. Discuss the exact step-down schedule with your prescriber before you leave.

What Tresiba Does Not Fix

Tresiba covers basal insulin needs only. Meal coverage still requires a rapid-acting insulin or, for type 2, whatever mealtime regimen you use. Jet lag-driven changes in appetite and meal timing mean your rapid-acting doses may need temporary adjustment. Keep a correction scale accessible and test more frequently for the first 48 hours after a major time-zone crossing.

Packing Insulin Degludec: Storage Rules You Cannot Skip

Insulin storage is where many travel plans break down. Get this wrong and your Tresiba loses potency before you ever need it.

Unopened Pens and Vials

Unopened Tresiba should be kept refrigerated between 36°F and 46°F (2°C to 8°C) until the expiration date printed on the label. A soft insulin travel case with a reusable ice pack handles most domestic flights. For checked luggage, be aware that cargo holds can freeze, which damages insulin. Always carry insulin in your personal item or carry-on.

In-Use Pens

Once you start using a Tresiba FlexTouch pen, it can be stored at room temperature below 86°F (30°C) for up to 56 days. That 56-day window is longer than most trips, which means if you begin a pen a few days before departure, it can travel without refrigeration for the duration of most vacations. Do not put an in-use pen back in the refrigerator; temperature cycling degrades the formulation.

Heat Exposure on the Road

Beach destinations and car travel in summer create real risk. A Frio evaporative cooling wallet or a similar non-ice cooling pouch keeps insulin below 86°F for hours without the freeze risk of ice packs. Check actual temperatures, not just the "feels like" number on your weather app, because inside a bag left in direct sun, temperatures can exceed 104°F within 20 minutes.

Navigating Time Zones: A Step-by-Step Framework

The following framework was developed by the WomanRx clinical team to help women on Tresiba manage injection timing across time zones without the guesswork.

Step 1: Calculate the time-zone difference. If you are traveling from New York (ET) to London (GMT), that is a 5-hour shift eastward.

Step 2: Determine direction of travel. Eastward travel shortens your day. Westward travel lengthens it.

Step 3: Apply the ±8-hour rule per travel day. For shifts of 8 hours or less, inject at your usual local time in the destination on arrival. Your body's Tresiba depot will tolerate the gap without meaningful hyperglycemia in most people.

Step 4: For shifts greater than 8 hours, use a two-day transition. On travel day 1, shift your injection by 4 hours toward the destination time. On travel day 2, shift the remaining difference. Check blood glucose before each injection and before bed.

Step 5: Test more, not less, for the first 48 hours. Target at least 4 finger-stick or CGM calibration checks per day during transition. If you use a CGM, confirm sensor readings against finger-sticks on the first day in a new destination, as altitude and temperature changes can affect CGM accuracy.

Step 6: Have a clear hypoglycemia rescue kit. 15 grams of fast-acting carbohydrate plus a glucagon kit (Gvoke, Baqsimi, or Zegalogue) should be in your carry-on, not checked luggage.

Women-Specific Factors That Change the Travel Equation

This is where a male-default diabetes travel guide falls short. Your hormonal environment directly changes how much insulin you need, and travel often coincides with hormonal variability.

Across the Menstrual Cycle

Estrogen and progesterone influence insulin sensitivity across the cycle. Research published in Diabetes Care (2015) and consistent clinical observation show that insulin resistance tends to rise in the luteal phase (the 12 to 14 days after ovulation) due to elevated progesterone. For women with type 1 diabetes, total daily insulin requirements can increase by 10 to 20 percent in the luteal phase. If a major trip falls mid-luteal phase, your basal needs may be higher than your usual home dose reflects. Track your cycle against your glucose trends for at least two cycles before a long international trip so you can anticipate the pattern.

Perimenopause

Perimenopause is one of the most destabilizing periods for blood sugar management, and it is underrepresented in diabetes travel literature. Estrogen decline reduces peripheral insulin sensitivity, while progesterone fluctuations add unpredictability. Hot flashes trigger cortisol bursts that drive transient hyperglycemia. A 2023 consensus statement from The Menopause Society acknowledged that metabolic changes in perimenopause increase the risk of type 2 diabetes, underscoring that glucose management in this life stage requires extra vigilance. If you are perimenopausal and on Tresiba, consider requesting a 1-week continuous glucose monitor trial before a major trip to see your real baseline variability.

Postpartum and Lactation

If you delivered recently and are breastfeeding while on Tresiba, insulin requirements typically drop sharply in the first weeks after delivery and may continue to shift with nursing frequency. Travel adds another variable. The FDA labeling for insulin degludec does not identify lactation-specific safety concerns, and insulin is a large-molecule protein that does not transfer meaningfully into breast milk at systemic levels. The American Diabetes Association Standards of Care support continued insulin therapy during lactation. Bring enough supplies for your infant's feeding schedule changes too, since any deviation in nursing frequency affects your caloric needs and therefore your insulin requirements.

Pregnancy, Lactation, and Contraception: The Full Picture

This section is required reading if you are pregnant, trying to conceive, or not using reliable contraception.

Tresiba carries an FDA Pregnancy Category B designation, based on animal reproduction studies that showed no harm to the fetus. Controlled data in pregnant women are limited. Most endocrinologists and OB-GYNs manage pregnant women with type 1 diabetes on insulin analogs that have longer track records in pregnancy, primarily NPH insulin or insulin glargine, based on ACOG Practice Bulletin No. 201 (Pregestational Diabetes Mellitus). Insulin degludec is not currently the first-choice basal insulin in pregnancy at most academic centers, not because of documented harm but because of the evidence gap.

If you become pregnant while on Tresiba, contact your endocrinologist and OB before your next injection. Do not stop basal insulin without guidance, as uncontrolled hyperglycemia in pregnancy carries clear risk to the fetus.

Trying to conceive: Preconception glycemic optimization matters. HbA1c targets below 6.5 percent before conception are associated with the lowest rates of congenital anomaly. If Tresiba is controlling your sugars better than alternatives, your care team may continue it while you are trying to conceive and switch you to a more studied agent once pregnancy is confirmed.

Contraception: Tresiba itself is not a teratogen at the level of drugs like valproate or isotretinoin, but any insulin-dependent woman planning to avoid pregnancy should use reliable contraception, since unintended pregnancy in the context of unoptimized diabetes carries significant risk. Combined hormonal contraceptives can modestly increase insulin resistance; discuss the method that fits your cardiovascular and metabolic profile with your prescriber.

Lactation: As noted above, insulin is not absorbed systemically from breast milk in meaningful amounts. Continuing Tresiba while breastfeeding is considered safe, with dose adjustments to account for the caloric demands of nursing.

TSA, Airport Security, and Documentation

The TSA Medical Conditions and Disabilities page confirms that insulin and insulin delivery devices are exempt from the standard 3.1-ounce liquid limit. You do not need to declare insulin, but you may. Needles and lancets are permitted when carried with the insulin.

Carry a letter from your prescriber on letterhead stating your diagnosis, your insulin type and dose, and the medical necessity of carrying needles and cooling packs. This prevents delays at international checkpoints where TSA rules do not apply. The letter should be in English and, for non-English-speaking destinations, translated or at minimum accompanied by a translation app backup.

Pack at minimum 150 percent of the insulin supplies you expect to need. Tresiba FlexTouch pens are not universally available outside the United States; in some countries, insulin degludec is sold under a different concentration (200 units/mL vs. The U-100 pens in the US) or a different product name. Carry your original pharmacy label to confirm the product name and concentration at international pharmacies if needed.

Living with Tresiba Day to Day: Beyond Travel

Travel is the focus here, but Tresiba's pharmacology shapes daily life in ways worth naming, because those patterns affect how you should prepare for any disruption in routine.

Flexibility in Meal Timing

Because Tresiba does not have a pronounced peak, skipping or delaying a meal carries less hypoglycemia risk from the basal component than it would with NPH insulin. If you use a rapid-acting insulin for meals, meal-skipping still requires adjustment of those doses. The BEGIN Flex T1 trial, which enrolled adults with type 1 diabetes, showed that flexible dosing of insulin degludec (intentional variation of up to 8 to 40 hours between injections) resulted in comparable HbA1c reduction and no significant increase in hypoglycemia compared with a fixed once-daily schedule, with an overall HbA1c reduction averaging 0.4 percentage points in that arm.

Exercise and Physical Activity

Physical activity lowers blood glucose acutely and can improve insulin sensitivity for 24 to 48 hours. Women need to know that the glucose-lowering effect of a single aerobic session can persist well into the next day. If your travel involves significantly more walking than your usual routine (sightseeing in Rome, hiking in national parks), plan for reduced basal needs. Some women reduce their Tresiba dose by 10 to 20 percent on days with sustained activity. Work out this adjustment with your diabetes care team before the trip rather than improvising at altitude.

Hypoglycemia on the Road

Hypoglycemia is more dangerous when you are away from your support network. The DEVOTE trial, a cardiovascular outcomes trial comparing insulin degludec to insulin glargine U-100 in over 7,600 adults, found that degludec was associated with a 40 percent lower rate of severe hypoglycemia (4.9 vs. 8.5 episodes per 100 patient-years; p < 0.001). That lower hypoglycemia rate is one of the drug's main clinical advantages for travel, but it does not mean hypoglycemia is impossible.

Always tell your travel companion where your glucagon kit is. If you are traveling alone, keep a medical ID bracelet visible and set a CGM low alert at a threshold that gives you time to act before you become confused.

PCOS, Insulin Resistance, and Tresiba

Women with polycystic ovary syndrome (PCOS) have a significantly elevated lifetime risk of type 2 diabetes, with one meta-analysis in Human Reproduction estimating a fourfold increased risk compared with women without PCOS. If you have PCOS-related type 2 diabetes and are on Tresiba, your insulin sensitivity is already lower at baseline and can fluctuate with your androgen levels and menstrual irregularity. This means travel-related glucose variability may be more pronounced. Consider requesting a CGM for any trip longer than three days.

Who This Is Right For, and Who Should Talk to Their Doctor First

Tresiba is likely a practical fit for travel if you:

• Have stable type 1 or type 2 diabetes on a once-daily basal regimen
• Are crossing fewer than 8 time zones, or are willing to do a two-day transition for larger shifts
• Have a current HbA1c that your care team considers travel-safe (generally below 8.5 percent)
• Have a glucagon rescue kit and know how to use it (or have a travel companion who does)

Talk to your prescriber before traveling if you:

• Are in the first trimester of pregnancy or actively trying to conceive
• Are perimenopausal with significant glucose variability on CGM
• Have had a severe hypoglycemic episode in the past 6 months
• Are traveling to a destination where altitude exceeds 8,000 feet, as altitude affects CGM accuracy and glucose metabolism
• Use insulin degludec 200 units/mL and need to source supplies internationally, since the 200 units/mL concentration is not available in all countries

A Note on the Evidence Gap for Women

Women have been underrepresented in the large insulin degludec outcomes trials. The DEVOTE trial included both sexes but did not publish sex-stratified hypoglycemia rates as a primary analysis. The BEGIN trial program similarly did not report on cycle-phase effects on degludec pharmacodynamics. Data on insulin degludec use during the perimenopausal transition are essentially absent from the published literature. The clinical guidance in this article draws on insulin pharmacology principles, PCOS and menopause endocrinology data, and patient-reported outcomes rather than randomized controlled trial evidence in women specifically. Where that extrapolation is being made, treat the recommendation as a framework to discuss with your own care team, not as a substitute for individualized clinical advice.